Background There is a substantial body of research evaluating ways to prevent and manage miscarriage, but all studies do not report on the same outcomes.
Introduction
Miscarriage is the commonest complication of pregnancy and is defined as a spontaneous pregnancy loss before the point of viability. It is clinically detected in around 15% of pregnancies.
1 Although miscarriage is the biggest cause of pregnancy loss in the UK, it remains poorly understood and there is a great deal of research focused on improving management and services for this condition. Clinical trials, systematic reviews, and guidelines have compared various interventions for the prevention and management of miscarriage. However, studies on miscarriage often do not address the same outcomes, making it difficult to draw conclusions when the evidence is synthesised. Variation in outcome reporting in other areas of women's health has been noted, e.g. in endometriosis, 2 pre-eclampsia 3 and infertility. 4 When designing randomised trials, selection of the most appropriate outcomes is of vital importance. The primary outcome should be the one that the research team considers to be the most important measure of effectiveness. Secondary outcomes should be selected in order to evaluate additional, important effects of the intervention under scrutiny. However, there may be no consensus within the clinical and research community or indeed across the wider society as to what constitutes the 'most important' clinical outcomes. In addition to disagreement regarding the relative importance of clinical outcomes, other factors can impact on outcome selection. These generally relate to feasibility, for example the ability reliably to measure an outcome, its prevalence, which will impact upon setting an achievable sample size, time limitations precluding the measurement of longer term events, and funding constraints. Investigators may also pragmatically favour the selection of outcomes which they believe will be more likely to result in a positive finding rather than choosing endpoints they consider the most important.
The diversity and bias in outcome reporting have been overcome by the creation of 'core outcome sets'. Core outcome sets are an agreed, standardised set of outcomes based on what key stakeholders (clinicians, patients, their partners, researchers, service developers, funding organisations, etc.) consider the important outcomes in the management or prevention of a condition. 5 Core outcome sets are now being widely developed and their use is advocated by governing institutes in the UK. 5, 6 An increased understanding about which outcomes are important to patients has the potential to act as a driver to improve both the quality and cost-effectiveness of miscarriage services. Our paper describes the systematic review undertaken to establish the outcomes used in trials evaluating prevention and management of miscarriage.
Methods
A comprehensive systematic review was performed to identify the outcomes used in randomised controlled trials (RCTs) evaluating prevention and management of miscarriage. Prevention included participants from the pre-conception period to pregnant patients presenting with symptoms, e.g. bleeding. Management included clinical management (expectant, medical and surgical) as well as psychological (quality of life) and financial (costs to health institutions). The systematic review was registered on PROSPERO International prospective register of systematic reviews (14/3/16, ID: PROSPERO 2016:CRD42016036349). The review was performed according to recommended methods for systematic reviews, and reported according to PRISMA guidelines. 7 
Data sources
The review assessed RCTs where investigation of prevention or management of miscarriage was the primary focus. MEDLINE (from 1966 to Jan 2017), Embase (from 1980 to Jan 2017), CINAHL (from 1981 to Jan 2017), and the Cochrane Central Register of Controlled Trial and clinical trial registries (to Jan 2017) were searched electronically. The Web of Science was used to search for grey literature. The search of MEDLINE, Embase, CINAHL and Cochrane captured citations containing the relevant MeSH keywords and word variants for 'miscarriage', 'spontaneous abortion' and 'pregnancy loss' (Supporting Information Appendix S1). Bibliographies of relevant articles were manually searched to identify papers not captured by the electronic searches. Authors were contacted for further information when necessary. There were no language restrictions in the search or selection of papers.
Eligibility criteria for selecting studies
Studies were selected if the focus of the paper was prevention or management of miscarriage and if they were randomised controlled trials. For miscarriage to be the focus of the paper, the population had to be women with recurrent miscarriage, or miscarriage was described as one of the main aims or outcomes appearing on the abstract. We restricted the inclusion of only randomised controlled trials to ensure that only studies of the highest quality were included. Miscarriage was defined as a pregnancy loss in the first trimester, the most common time of gestation for pregnancy loss to occur. The decision to exclude second trimester pregnancy loss was made because underlying pathologies and prevention strategies differ substantially from those underpinning pregnancy loss in the first trimester pregnancy such that relevant outcomes would diverge. For example, second trimester pregnancy loss is thought to be associated with cervical weakness, genital tract infection and pre-eclampsia necessitating specific prevention strategies, namely cervical cerclage, genital tract infection surveillance and the use of low-dose aspirin. Thus, attempts to merge interventions to prevent first and second trimester pregnancy losses would result in an overly complex analysis and difficulty extrapolating and comparing results.
Studies were selected in a two-stage process. Initially, all abstracts or titles in the electronic searches were scrutinised by two reviewers (PS and RDS), and full manuscripts of potentially eligible citations were obtained.
Data extraction
Data were extracted by two reviewers (PS and RDS). All primary and secondary outcomes were recorded. For the prevention papers, data were extracted according to the clinical presentation: asymptomatic (which included both pre-conception and pregnant women) or symptomatic (women with bleeding in pregnancy). For the management papers, data were extracted for the type of miscarriage management (medical, surgical or expectant) or whether the study was evaluating psychological or quality of life outcomes.
The study aims and outcome information were collected using a customised data extraction form. Primary and secondary outcomes were categorised into summary domains but specific outcome definitions and measures were sought pertaining to each domain. Any differing opinions in categorisation were discussed with reviewers (AC and TJC). Categorisation and terminology were also checked by the patient representative (EO) to ensure they made sense in lay terms. When studies did not state what the primary outcome was, if available the outcome used for the sample size calculation was designated as the primary outcome. Data were also extracted using a taxonomy suggested by Dodd et al. 8 The four core outcomes defined by Dodd et al. are mortality/survival, physiological/clinical, functioning and resource use.
Specific data were extracted where relevant; i.e., if 'pregnancy loss' was an outcome, the reviewers sought to report the measure used to define the gestational age of pregnancy loss, e.g. before 14 weeks and before 24 weeks. Data were also collected regarding year of study, study design, sample size, multicentre vs single centre and whether the overall findings were positive or negative.
Quality assessment
All articles meeting the selection criteria were assessed for quality using the Cochrane tool of bias. 9 The quality of the outcome reporting was also assessed using the MOMENT criteria.
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Funding
The research costs of the systematic review were funded by the National Institute for Health Research (NIHR), reference: PDF-2015-08-099. This review is part of an ongoing project to develop a core outcome set for miscarriage research.
Results
Prevention of miscarriage
The search strategy identified 1553 titles and abstracts. A total of 94 RCTs were included in the review (Table S1) .
11- 104 The PRISMA flow chart in Supporting Information Figure S1 shows study selection. Table 1 displays the study characteristics for the included papers. The majority of trials (80/94, 85%) evaluated prevention in asymptomatic women (i.e. looking to prevent miscarriage before any signs of threat to the pregnancy, such as bleeding, developed). Nearly half of the trials (52/94, 48%) had a sample size of <100.
The outcomes collected and reported in the included trials were grouped into six outcome domains (new born/child; pregnancy; maternal complications; laboratory investigations; fetal; economic). The specific primary outcomes reported, grouped by domain, for each of the 94 trials are listed in Table 2 . The most commonly used primary outcome was live birth, which was reported in 41/94 (44%) of the included miscarriage prevention trials.
The specific outcomes, whether used as primary or secondary endpoints, and the number of times each outcome was reported are displayed in Supporting Information Table S2 . Across the five outcome domains, 112 different outcomes were reported. Of these outcomes, the four most frequently reported were pregnancy loss/stillbirth (n = 112), gestation of birth (n = 68), birth dimensions (n = 65), and live birth (n = 49). It should be appreciated that the number of times a particular outcome was reported did not always correlate with the number of trials reporting that outcome because often a trial would use more than one outcome measure for the same outcome. For example, the outcome of 'birth dimension' may have been measured and reported in a particular trial using the outcome measures of birthweight, birth length, and head circumference. In this situation, the number of times the specific outcome of birth dimension was reported would be counted as three.
The number and variety of outcome measures used for the four most popular outcomes are detailed in Supporting  Information Tables S3-S6 .
Pregnancy loss and stillbirth were included together as an outcome because of heterogeneity in definition and a lack of detail in reporting (e.g. 'pregnancy loss after 10 weeks' to define pregnancy loss), precluding reliable distinction between a miscarriage and a stillbirth. This variation in the assessment of pregnancy loss/stillbirth is demonstrated by the use of 27 different measures (Table S3) . Birth dimension was measured in 11 different ways, with the majority of outcomes using birthweight as a continuous variable or dichotomising by either a fixed weight (e.g. birthweight <2500 g) or using a growth chart centile (e.g. birthweight <10th centile) (Table S4) . Fourteen different outcome measures were used to report the gestation at birth. Gestation was either measured and reported as a continuous variable in completed weeks or dichotomised to measure preterm birth. However, there was wide variation in the way preterm birth was defined, with 13 different measures employed (Table S5) . Live birth was the most commonly reported primary outcome and fourth most common overall when secondary outcome reporting was also taken into account. When defined, live birth was measured in seven different ways, although most miscarriage prevention trials (83%) reporting this outcome failed to provide a definition for what constituted a live birth (Table S6) .
There were 49 different outcomes reported 190 times in the domain of maternal complications, but only five outcomes appeared in ten or more trials: thrombocytopenia (n = 24), pre-eclampsia (n = 23), bleeding not specified (n = 16), antepartum bleeding (n = 11), and placental abruption (n = 11).
Mode of delivery was reported 18 times and was the most commonly reported outcome in the fetal domain. The most commonly reported laboratory investigation was serum progesterone, recorded four times. Admission of the child to specialised care was the most common outcome within the economic domain, being reported ten times (Table S2) .
The data have also been presented using the taxonomy suggested by Dodd et al 8 (Table S7 ). There were no outcomes assessing quality of life or patient perspectives in any of the prevention trials.
Management of miscarriage
A total of 114 RCTs were included in the review. The PRISMA flow chart in Figure S1 shows study selection. The included trials collected and reported 12 different primary outcomes; 4/114 (9%) studies did not specify a primary outcome. The primary and secondary outcomes defined and reported across the studies categorised into a summary domain are displayed in Table 3 .
The specific outcomes and the number of times each outcome was reported are displayed in Table S8 . A total of 130 different outcome measures were used to evaluate the four most commonly reported clinical outcomes (bleeding, quality of life, efficacy of miscarriage treatment, and infection) (Supporting Information Tables S9-S12) . A wide variety of maternal symptoms were reported (n = 37; Table S8 ). In many trials more than one outcome was reported within a particular domain (Table S8) .
Assessment of bleeding was reported 186 times across 76/114 (67%) studies. There were 26 different ways in which it was measured, and these are described in Table S9 . The most commonly reported measure of blood loss was 'days of bleeding' (n = 32). The second most commonly reported outcome was efficacy of treatment, which was reported 105 times across 78/114 (68%) studies with 34 different measures used to assess efficacy (Table S10) . The most common measure to assess efficacy was whether no additional surgical intervention was needed (n = 31). The outcome of infection was reported 97 times across 64/ 114 (56%) studies with 30 different measures of infection recorded (Table S11 ). The most common measures were 'any fever or chills' (n = 11) as defined by the patient or 'general infection' (n = 11). The outcome quality of life was reported 90 times across 32/114 (28%) trials. There were 40 different measures used to assess quality of life; the hospital anxiety and depression scale was the most common tool used for assessment (n = 11) (Table S12) .
Economic outcomes were reported in 54/114 (47%) trials. The most common economic outcome was duration of treatment (n = 34), followed by unscheduled medical visits (n = 23) (Table S8 ). Patient perspective outcomes were reported 103 times in 45/114 (39%) trials. There were eight different outcomes, the most common being patient satisfaction (n = 26), closely followed by 'would you choose the method again?' (n = 25) (Table S8 ). Fertility outcomes were only reported in 8/114 (7%) of studies. The only fertility outcome collected was conception except in one study, 106 which also collected data on miscarriage and ectopic rates in future pregnancies.
The data were also extracted in line with the suggested taxonomy by Dodd et al., 8 and this is presented in Supporting Information Table S13. A comparison of outcomes among the largest studies (n > 1000) for both miscarriage prevention and management is presented in Supporting Information Table S14.
Quality assessment
All studies were assessed for bias using the Cochrane tool of bias, and these results are displayed in Supporting Information Figure S2 . The majority of miscarriage studies were low risk for each of the bias criterion with the exception of blinding of participants and outcome assessments. This reflected the finding that many studies compared two different management strategies such that blinding was not always possible. The quality of outcome reporting is shown in Supporting Information Figure S3 . The majority of studies clearly stated a primary outcome (196/208, 94%) and secondary outcomes (194/208, 93%) , but often did not specify a definition. The explanation for choice of outcome was poorly recorded (25/208, 12%) as were methods to improve outcome measurement (10/208, 5%). 
Discussion
Main findings
This systematic review has identified the outcomes that are most commonly used and the way they are measured for trials studying miscarriage prevention and management. The four most commonly reported outcomes in prevention of miscarriage trials are pregnancy loss/stillbirth, birth dimensions, gestation of birth, and live birth. The four most commonly reported outcomes in management of miscarriage trials are efficacy of treatment, bleeding, infection, and quality of life.
Strengths and limitations
The originality and robust methodology are key strengths of this review. To our knowledge, this is the first systematic review to describe outcome reporting variation in trials studying miscarriage prevention and management. Restricting the inclusion criteria to only RCTs means there may be missed outcomes which are only present in observational studies. However, the justification for this is that RCTs are considered to have the highest quality among interventional studies and so should include all the most important and relevant outcomes. Moreover, despite restricting the inclusion criteria to RCTs, there were still 208 studies included in this review, which means that we are likely to have gathered outcomes important to researchers. One limitation of this work was the degree of subjectivity relating to the definition of outcome domains and specific outcomes groupings. Consensus among the authors, which included a patient representative, was used to agree categorisation of outcomes.
Interpretation
One of the difficulties in performing a randomised controlled trial on women with recurrent miscarriage is finding enough eligible patients. This could explain why nearly half of the included trials had a sample size <100. For a study to reduce recurrent miscarriage from 40% to 30%, with 80% power at an alpha level of 0.05% there would need to be at least 376 per arm before even loss to follow up is considered. This suggests that most studies were underpowered to show clinically significant differences in treatment. In addition, miscarriage is associated with serious psychological and physical morbidity, so being able to show a small reduction in miscarriage rate, which requires larger study samples, could be clinically worthwhile. Thus, even though miscarriage is common, it appears that trials studying women with recurrent miscarriage struggle to find enough eligible patients. This highlights still further the importance of a harmonised outcome set so that studies can be combined to find more powerful answers to research questions.
The most commonly reported outcome for prevention trials was pregnancy loss/stillbirth. Interestingly, in over half of these studies there was no actual definition for the measurement of outcome. For trials evaluating prevention of first trimester losses, it may make sense to have the end of the first trimester as the cut-off for success. However, it is becoming common practice to have live birth as the primary outcome for miscarriage trials, as this is ultimately the desired outcome. When using live birth as a primary outcome, it is also important to have a pre-specified gestation. For example, a minimum gestation, such as 34 weeks, where clinical prognosis is invariably good, could be the measured desired outcome. A separate but important issue is the choice of denominator when using live birth as an outcome. There is debate among trialists about whether to use the number of women who became pregnant or the total number randomised. The choice of denominator naturally affects the overall percentages and thus could introduce bias. This is a factor for consideration when trying to streamline future miscarriage trials to allow for direct comparison of data.
Bleeding was the most commonly reported outcome for the miscarriage management trials; however, 26 different measures were used to assess bleeding. A fall in haemoglobin would seem a more objective measure of blood loss than subjective measures such as 'number of sanitary pads used' or self-report of 'any heavy bleeding'. However, to achieve consensus regarding how best to assess blood loss during miscarriage requires knowledge of all outcomes and discussion by all relevant stakeholders. By highlighting these inconsistencies in outcome measurement, information from our review can inform such a process.
Our study findings are consistent with those of other systematic reviews on outcome reporting in women's health in showing wide variation in reporting of outcomes. 5, 6 We propose that researchers should use agreed, common outcomes that are measured in a standardised fashion. Development and implementation of a core outcome set in future clinical miscarriage trials will allow better data synthesis, meta-analysis, and comparison of work aiding interpretation and facilitating timely and appropriate clinical applications.
Conclusion
Our review has demonstrated great disparity in the reporting of primary and secondary outcomes and the measures used to assess them in miscarriage prevention and management trials. Such inconsistency across outcomes can lead to research that is not comparable, limiting the strength of clinical inferences and recommendations for clinical practice. This is particularly important for a subject such as miscarriage prevention where there are still so many unanswered questions. There is a clear need for standardised patient-centred clinical outcomes through the development of a core outcome set. Until this is developed, we recommend that for prevention of miscarriage trials, the key outcomes reported should be live birth, pregnancy loss/ stillbirth, birth dimensions (measured as birthweight), gestation of birth, and adverse maternal events. For the miscarriage management trials, the recommended key outcomes should be efficacy of treatment (successful evacuation of products of conception from the uterus and quality of life) and adverse effects relating to bleeding and infection.
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